Oregon's health authority reviewing UnitedHealth's acquisition of Amedisys
- Amedisys said on Tuesday Oregon's health authority has started a review of UnitedHealth Group's $3.3 billion acquisition of the home health and hospice caregiver.
- 03/19/2024
|
AMED vs. USPH: Which Stock Is the Better Value Option?
- Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?
- 02/22/2024
|
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
- While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 02/21/2024
|
Amedisys (AMED) Q4 Earnings Lag Estimates
- Amedisys (AMED) came out with quarterly earnings of $0.94 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.16 per share a year ago.
- 02/21/2024
|
Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/14/2024
|
Amedisys (AMED) Up 2.6% Since Last Earnings Report: Can It Continue?
- Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
- 11/23/2023
|
Amedisys, Inc.: Why Stock Is A Hold Pending Agency Review
- Amedisys, Inc. is set to be acquired by UnitedHealth Group in a $3.29 billion merger agreement. Some US legislators have called for further scrutiny of the merger, citing concerns of increased market dominance and higher medical costs. UnitedHealth's subsidiary, Optum Group, has been expanding its service provision through acquisitions, including a recent deal with UK health-tech company EMIS Group.
- 11/03/2023
|
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
- Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 10/24/2023
|
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
- Amedisys (AMED) came out with quarterly earnings of $0.98 per share, missing the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.15 per share a year ago.
- 10/24/2023
|
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
- Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.
- 10/18/2023
|
Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip
- Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.
- 07/28/2023
|
Amedisys (AMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 07/26/2023
|
Dow Jones Today: Index Plunges on Strong Jobs Data
- The Dow Jones Industrial Average fell 1.1%, or 366 points, Thursday after private sector payroll data showed that the labor market remains strong, raising fears that the Federal Reserve could hike rates faster or higher than planned.
- 07/06/2023
|
Amedisys (AMED) to Advance Value-Based Care With Optum Merger
- Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.
- 06/28/2023
|
UnitedHealth's Amedisys Deal Come as Home Health and Data Cement Care Ecosystems
- In healthcare, the latest acquisition brings to mind that old Fred Astaire song lyric: “Won't you change partners and dance with me?” On Monday, as had been reported here, Amedisys, the home health and hospice firm, agreed to be acquired by UnitedHealth's Optum.
- 06/26/2023
|
UnitedHealth Buys Amedisys for $3.3 Billion
- UnitedHealth Group outbid Option Care's offer to buy home healthcare provider Amedisys.
- 06/26/2023
|
Amedisys Agrees to $3.3 Billion UnitedHealth Merger
- Home health company Amedisys has agreed to a $3.3 billion merger with UnitedHealth Group. The deal calls for the acquisition of Amedisys' outstanding common stock in an all-cash transaction for $101 per share and places Amedisys under the umbrella of UnitedHealth's Optum arm, according to a Monday (June 26) press release.
- 06/26/2023
|
UnitedHealth Agrees All-Cash Deal to Buy Amedisys
- The move for the healthcare-service provider is worth $101 a share.
- 06/26/2023
|
Amedisys agrees to UnitedHealth buyout offer, scraps Option Care deal
- Amedisys Inc on Monday agreed to acquired by UnitedHealth Group for $101 per share in cash, and terminated an all-stock deal to be bought by Option Care Health Inc.
- 06/26/2023
|
Amedisys agrees to merge with UnitedHealth, and terminates deal with Option Care Health
- Amedisys Inc. AMED, -0.15% disclosed Monday that it has agreed to merge with UnitedHealth Group Inc. UNH, -0.43%, and terminated its merger with Option Care Health Inc. OPCH, +1.47% agreed on in early-May. Under terms of deal with UnitedHealth, each Amedisys share will be converted into the right to receive $101 in cash, which represents as 10.7% premium to Friday's closing price of $91.21.
- 06/26/2023
|
4 Stocks to Hold in a Challenging Outpatient Home Health Industry
- Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE, AMED and ADUS are well poised to gain.
- 06/14/2023
|
Amedisys: Even Without A Bidding War, The Company Appears Undervalued
- Amedisys is a leading healthcare services company dedicated to providing clinically excellent care and support at home. Currently reporting FCF generation and proposing workforce optimization, clinical optimization, and reorganization initiatives to differentiate service offerings, Amedisys appears quite an attractive stock. If the Board recommends the offer from Option Care Health, we may see an increase in the stock price.
- 06/09/2023
|
Strength Seen in Amedisys (AMED): Can Its 15.4% Jump Turn into More Strength?
- Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 06/06/2023
|
Why Shares of Amedisys Are Jumping Monday
- Optum's new buyout offer is competing with another buyout offer from Option Care Health. This latest offer would be a $3.26 billion all-cash deal.
- 06/05/2023
|
Amedisys rallies on $3.26B unsolicited bid from UnitedHealth's Optum
- Amedisys Inc told investors it received an unsolicited $100 per share bid from UnitedHealth Group's Optum unit that may be ‘superior' to a planned merger with Option Care Health, sending its shares higher in early Monday trade. The Baton Rouge, Louisiana-based healthcare company already agreed to merge with Option Care Health in an all-stock transaction in a deal announced on May 3, 2023.
- 06/05/2023
|
Amedisys received unsolicited buyout bid from Optum that could be ‘superior' to deal with Option Care Health
- Amedisys Inc. AMED, +3.64% disclosed Monday that it had received an unsolicited cash buyout bid for $100 a share from Optum, which the at-home healthcare services company believes could be considered “superior” to the buyout deal already agreed on with Option Care Health Inc. OPCH, +2.99% in early May. Amedisys shares were still inactive in premarket trading while Option Care's stock rallied 4.7%.
- 06/05/2023
|
Amedisys gets over $3 billion unsolicited offer from UnitedHealth's Optum
- Amedisys Inc said on Monday it had received an unsolicited proposal from UnitedHealth Group's health services company Optum to acquire all of its outstanding shares in an all-cash transaction worth $3.26 billion.
- 06/05/2023
|
Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip
- Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
- 05/04/2023
|
Amedisys (AMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 05/03/2023
|
Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable
- For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.
- 04/14/2023
|
Here's Why You Should Retain Amedisys (AMED) Stock for Now
- Amedisys's (AMED) share price is likely to grow following an impressive fourth-quarter 2022 performance and new partnerships.
- 04/04/2023
|
Amedisys to Present at Multiple Healthcare Conferences in March
- BATON ROUGE, La., March 09, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Paul Kusserow, Chairman and Chief Executive Officer and Scott Ginn, Acting Chief Operating Officer, Executive Vice President and Chief Financial Officer, will present at Oppenheimer's 33rd Annual Healthcare Conference on March 14th at 10:00 a.m. ET and at the Barclays Global Healthcare Conference on March 15th at 8:50 a.m. ET.
- 03/09/2023
|
Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips
- Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.
- 02/17/2023
|
Amedisys, Inc. (AMED) Q4 2022 Earnings Call Transcript
- Amedisys, Inc. (NASDAQ:AMED ) Q4 2022 Earnings Conference Call February 16, 2023 11:00 AM ET Company Participants Nick Muscato - Chief Strategy Officer Paul Kusserow - Chairman & CEO Scott Ginn - EVP, CFO & Acting COO Adam Holton - Chief People Officer Conference Call Participants Brian Tanquilut - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank Joanna Gajuk - Bank of America Merrill Lynch Andrew Mok - UBS Tao Qiu - Stifel, Nicolaus & Company Benjamin Hendrix - RBC Capital Markets Benjamin Mayo - SVB Securities John Ransom - Raymond James & Associates Scott Fidel - Stephens Inc. Gary Taylor - Cowen and Company A.J. Rice - Crédit Suisse Operator Greetings and welcome to the Amedisys Fourth Quarter 2022 Earnings Conference Call.
- 02/16/2023
|
Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates
- Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/15/2023
|
Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Dates
- BATON ROUGE, La., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the fourth quarter and year ended December 31, 2022, after the market closes on February 15, 2023. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 16, 2023.
- 01/30/2023
|
Amedisys (AMED) Faces Macro Challenges, Margin Pressure
- The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.
- 01/05/2023
|
Amedisys to Present at the 41st Annual J.P. Morgan Healthcare Conference
- BATON ROUGE, La., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 8:15 p.m. ET (5:15 p.m. PT).
- 12/28/2022
|
Amedisys to Present at Bank of America Securities Home Care Conference
- BATON ROUGE, La., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer and Scott Ginn, Chief Operating Officer, will present at the Bank of American Securities Home Care Conference on Tuesday, December 6 at 9 a.m. ET.
- 12/02/2022
|
Amedisys: No Change To Thesis, Retain Hold
- Company CEO departed last week, although management reaffirmed FY22 guidance. Speaking of guidance, growth at the top–bottom lines was narrowed down on the Q3 earnings call.
- 11/23/2022
|
Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut
- Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.
- 10/31/2022
|
Amedisys, Inc. (AMED) Q3 2022 Earnings Call Transcript
- Amedisys, Inc. (NASDAQ:AMED ) Q3 2022 Earnings Conference Call October 27, 2022 11:00 AM ET Company Participants Nick Muscato – Chief Strategy Officer Chris Gerard – President and Chief Executive Officer Scott Ginn – Executive Vice President and Chief Financial Officer Conference Call Participants Brian Tanquilut – Jefferies Matt Larew – William Blair Justin Bowers – Deutsche Bank A.J. Rice – Credit Suisse Sarah James – Barclays Ben Hendrix – RBC Capital Markets Bill Sutherland – Benchmark Company John Ransom – Raymond James Scott Fidel – Stephens Whit Mayo – SVB Securities Tao Qiu – Stifel Andrew Mok – UBS Joanna Gajuk – Bank of America Operator Greetings.
- 10/27/2022
|
Amedisys (AMED) Misses Q3 Earnings and Revenue Estimates
- Amedisys (AMED) delivered earnings and revenue surprises of -7.26% and 3.41%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 10/26/2022
|
3 Stocks to Watch From the Pandemic-Hit Outpatient Home Health Industry
- Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. AMED, ADUS and HNGR are well poised to gain from the prospects.
- 09/29/2022
|
Here's Why Investors Should Retain Amedisys (AMED) Stock for Now
- Investors are optimistic about Amedisys' (AMED) better-than-expected earnings and notable buyouts.
- 09/23/2022
|
Amedisys Inc (AMED) CEO Chris Gerard on Q2 2022 Results - Earnings Call Transcript
- Amedisys Inc (NASDAQ:AMED ) Q2 2022 Earnings Conference Call July 28, 2022 11:00 AM ET Company Participants Nick Muscato - Chief Strategy Officer Chris Gerard - President and Chief Executive Officer Scott Ginn - Executive Vice President and Chief Financial Officer David Kemmerly - Chief Legal and Government Affairs Officer Conference Call Participants Brian Tanquilut - Jefferies Matt Larew - William Blair Justin Bowers - Deutsche Bank John Ransom - Raymond James Benjamin Rossi - BMO Sarah James - Barclays A.J. Rice - Crédit Suisse Michael Murray - RBC Andrew Mok - UBS Tao Qiu - Stifel Scott Fidel - Stephens Whit Mayo - SVB Securities Nabil Gutierrez - BofA Securities Operator Greetings.
- 07/28/2022
|
Amedisys (AMED) Q2 Earnings Beat Estimates
- Amedisys (AMED) delivered earnings and revenue surprises of 19.51% and 4.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/27/2022
|
Amedisys Announces Second Quarter 2022 Earnings Release and Conference Call Date
- BATON ROUGE, La., July 06, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the second quarter ended June 30, 2022, after the market closes on July 27, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on July 28, 2022.
- 07/06/2022
|
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
- Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
- 06/28/2022
|
Amedisys (AMED) Contessa's New JV Broadens At-Home Care Range
- Amedisys' (AMED) latest initiative aims at providing patients with a high-quality continuum of care in the home.
- 06/10/2022
|
Amedisys (AMED) Down 11% Since Last Earnings Report: Can It Rebound?
- Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
- 05/27/2022
|
Here's Why You Should Retain Amedisys (AMED) Stock for Now
- Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.
- 05/25/2022
|
Amedisys to Present at Multiple Healthcare Conferences in June
- BATON ROUGE, La., May 25, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Chris Gerard, President and Chief Executive Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present and conduct investor one-on-ones at the Benchmark Healthcare House Calls Conference on Thursday, June 2, the William Blair 42nd Annual Growth Stock Conference on Monday, June 6 at 2 p.m. CST and the Jefferies Healthcare Conference on Wednesday, June 8 from 3:30-3:55 p.m. ET.
- 05/25/2022
|
Amedisys (AMED) New Buyouts Aid Growth, Margin Pressure Stays
- Amedisys' (AMED) newly-formed high-acuity care segment experiences solid momentum in the first quarter.
- 05/11/2022
|
Amedisys to Present at Multiple Healthcare Conferences in May
- BATON ROUGE, La., April 29, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care, today announced that Chris Gerard, President and Chief Executive Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer, will present and conduct investor one on ones at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, at 5:40 p.m. ET, the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, and the UBS Global Healthcare Conference on Monday, May 23, at 9:15 a.m. ET.
- 04/29/2022
|
Amedisys, Inc. (AMED) CEO Christopher Gerard on Q1 2022 Results - Earnings Call Transcript
- Amedisys, Inc. (NASDAQ:AMED ) Q1 2022 Earnings Conference Call April 28, 2022 11:00 AM ET Company Participants Nick Muscato - Chief Strategy Officer Christopher Gerard - CEO, President & Director Scott Ginn - EVP & CFO David Kemmerly - Chief Legal & Government Affairs Officer Conference Call Participants Brian Tanquilut - Jefferies Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank John Ransom - Raymond James & Associates Matthew Borsch - BMO Capital Markets Andrew Mok - UBS Benjamin Mayo - SVB Leerink Sarah James - Barclays Bank Joanna Gajuk - Bank of America Merrill Lynch Albert Rice - Crédit Suisse Operator Greetings, and welcome to Amedisys' Q1 '22 Earnings Conference Call. [Operator Instructions].
- 04/28/2022
|
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Down
- Impressive performance by the Home Health and Hospice segments drove Amedisys' (AMED) revenues in the first quarter.
- 04/28/2022
|
Amedisys Announces First Quarter 2022 Earnings Release and Conference Call Date
- BATON ROUGE, La., April 13, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the first quarter ended March 31, 2022, after the market closes on April 27, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on April 28, 2022.
- 04/13/2022
|
Why Is Amedisys (AMED) Up 13.2% Since Last Earnings Report?
- Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
- 03/25/2022
|
New Strong Sell Stocks for March 9th
- AGESY, AMED, and APAM have been added to the Zacks Rank #5 (Strong Sell) List on March 9, 2022.
- 03/09/2022
|
Amedisys to Present at Multiple Healthcare Conferences in March
- BATON ROUGE, La., March 08, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris Gerard, President and Chief Operating Officer, and Scott Ginn, Executive Vice President and Chief Financial Officer, will present at Oppenheimer's 32nd Annual Healthcare Conference on March 16 at 10:40 a.m. EST and at the Barclays Global Healthcare Conference on March 17 at 8:00 a.m. EST.
- 03/08/2022
|
New Strong Sell Stocks for March 4th
- AMED, CACC, and EXPO have been added to the Zacks Rank #5 (Strong Sell) List on March 4, 2022
- 03/04/2022
|
Amedisys to Present at the Raymond James & Associates' 43rd Annual Institutional Investors Conference
- BATON ROUGE, La., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer, will present at the Raymond James & Associates' 43rd Annual Institutional Investors Conference on Tuesday, March 8, at 11:35 a.m. EST.
- 02/28/2022
|
Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2021 Results - Earnings Call Transcript
- Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2021 Results - Earnings Call Transcript
- 02/24/2022
|
Amedisys (AMED) Beats Q4 Earnings and Revenue Estimates
- Amedisys (AMED) delivered earnings and revenue surprises of 0.86% and 0.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/23/2022
|
Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date
- BATON ROUGE, La., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the fourth quarter and year ended December 31, 2021, after the market closes on February 23, 2022. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 24, 2022.
- 01/31/2022
|
Amedisys to Present at the 40th Annual J.P. Morgan Healthcare Conference
- BATON ROUGE, La., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high-acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, at 3:45 p.m. EST.
- 12/29/2021
|
New Strong Sell Stocks for December 29th
- B, FPI, CGNX, AMED, and FSUGY have been added to the Zacks Rank #5 (Strong Sell) List on December 29, 2021.
- 12/29/2021
|
New Strong Sell Stocks for December 27th
- TXRH, VIOT, WBK, AMED and CGNX have been added to the Zacks Rank #5 (Strong Sell) List on December 27, 2021
- 12/27/2021
|
10 Bargain Stocks to Buy After Falling 30% in 2021
- If you're looking for bargain stocks to buy that are down 30% or more in 2021, that's not an easy task. Here are 10 that fit the bill.
- 12/20/2021
|
New Strong Sell Stocks for December 2nd
- AMED, LGIH, SWK, TCMD, and HEINY have been added to the Zacks Rank #5 (Strong Sell) List on December 2, 2021.
- 12/02/2021
|
Amedisys to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
- BATON ROUGE, La., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Bank of America Securities 2021 Virtual Healthcare Conference on December 6 at 9:00 a.m. Eastern.
- 11/30/2021
|
New Strong Sell Stocks for November 26th
- COLD, ENR, KSU, FSTR, and AMED have been added to the Zacks Rank #5 (Strong Sell) List on November 26, 2021.
- 11/26/2021
|
New Strong Sell Stocks for November 19th
- AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.
- 11/19/2021
|
Amedisys to Present at the Stephens Annual Investment Conference
- BATON ROUGE, La., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Stephens Annual Investment Conference on December 3rd at 10:00 am Eastern.
- 11/19/2021
|
New Strong Sell Stocks for November 5th
- BLMN, AMED, HL, LGIH, and PLMR have been added to the Zacks Rank #5 (Strong Sell) List on November 5, 2021.
- 11/05/2021
|
Amedisys to Present at the Jefferies London Healthcare Conference
- BATON ROUGE, La., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and higher acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer and Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Jefferies London Healthcare Conference on November 18th at 3:00 pm Eastern.
- 11/04/2021
|
Amedisys (AMED) Tops Q3 Earnings Estimates, Slashes '21 View
- Amedisys (AMED) reports better-than-expected earnings for the third quarter on strong growth in the Home Health segment.
- 11/03/2021
|
Amedisys, Inc's (AMED) CEO Paul Kusserow on Q3 2021 Results - Earnings Call Transcript
- Amedisys, Inc's (AMED) CEO Paul Kusserow on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Analysts Estimate Amedisys (AMED) to Report a Decline in Earnings: What to Look Out for
- Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/26/2021
|
Amedisys Announces Third Quarter Earnings Release and Conference Call Date
- BATON ROUGE, La., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and higher acuity care services, will report results for the third quarter ended September 30, 2021, after the market closes on November 2, 2021. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on November 3, 2021.
- 10/13/2021
|
Can Amedisys Stock Rebound After A 5% Fall In A Week?
- Last month, we discussed that Amedisys stock price could rebound over a one-month period after falling 3% in a week, based on its historical performance. However, AMED stock has seen a further decline of over 9% since then, and it is down 5% in the last five trading days.
- 09/27/2021
|
Amedisys to Acquire Home Health Regulatory Assets in Charlotte and Raleigh, N.C.
- BATON ROUGE, La., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire regulatory assets that allow the Company to establish home health care centers to fully service and expand the Charlotte and Raleigh, N.C. markets.
- 09/20/2021
|
EHC or AMED: Which Is the Better Value Stock Right Now?
- EHC vs. AMED: Which Stock Is the Better Value Option?
- 09/13/2021
|
Amedisys (AMED) Down 6.5% Since Last Earnings Report: Can It Rebound?
- Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
- 09/03/2021
|
7 Stocks to Buy That Could Benefit From Democrats Spending Big
- Investors can capitalize on Democratic spending no matter their affiliation. Here are the stocks to buy based on boosts in renewables, health care and infrastructure.
- 08/31/2021
|
Will Amedisys Stock Rebound After Hitting Its 52-Week Low?
- The stock price of Amedisys, a home-health and hospice company, reached its 52-week low of $175 in yesterday's trading session. AMED stock has seen a gradual decline from levels of over $310 in Jan and Feb this year to levels of around $250 earlier this month, before a recent sell-off in the stock.
- 08/25/2021
|
EHC vs. AMED: Which Stock Should Value Investors Buy Now?
- EHC vs. AMED: Which Stock Is the Better Value Option?
- 08/11/2021
|
Amedisys (AMED) Suffers From Low Occupancy Amid Pandemic
- The prolonged and lingering impact of COVID-19 on Amedisys (AMED) Hospice business has hampered its ability to grow at the earlier-projected rates.
- 08/11/2021
|
Amedisys, Inc. (AMED) CEO Paul Kusserow on Q2 2021 Results - Earnings Call Transcript
- Amedisys, Inc. (AMED) CEO Paul Kusserow on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Why Amedisys Stock Is Crashing Today
- The company provided disappointing full-year guidance.
- 08/05/2021
|
Amedisys Reports Second Quarter 2021 Financial Results, Closing of Contessa Acquisition, Expansion of Credit Facility and Authorization of New $100 Million Share Repurchase Program
- BATON ROUGE, La., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2021.
- 08/04/2021
|
Healthcare Stock Needs a Post-Earnings Pop
- Amedisys, Inc. (NASDAQ:AMED) is one of the largest home health providers and second largest hospice care provider in the U.S. In the thick of earnings season , the company will step into the confessional tomorrow after the close.
- 08/03/2021
|
EHC or AMED: Which Is the Better Value Stock Right Now?
- EHC vs. AMED: Which Stock Is the Better Value Option?
- 07/26/2021
|
Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity
- Amedisys announces the acquisition of Contessa Health, a leader in hospital-at-home services. Despite the near-term margin drag, the added growth potential and strategic benefits should drive upside to the longer-term earnings trajectory.
- 07/18/2021
|
EHC or AMED: Which Is the Better Value Stock Right Now?
- EHC vs. AMED: Which Stock Is the Better Value Option?
- 07/08/2021
|
Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice
- Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.
- 07/08/2021
|
Amedisys' (AMED) Contessa Buyout to Boost Home Health Business
- Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.
- 07/02/2021
|
Amedisys (AMED) Soars 6.7%: Is Further Upside Left in the Stock?
- Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
- 07/02/2021
|
Amedisys Announces Agreement to Acquire Contessa Health, Creating a Comprehensive Home Healthcare Delivery Platform
- Strategic acquisition will add tech-enabled, higher-acuity hospital at home and skilled-nursing facility at home services, advanced claims analytics platform, network management and additional risk-taking capabilities to Amedisys' range of home-based services Strategic acquisition will add tech-enabled, higher-acuity hospital at home and skilled-nursing facility at home services, advanced claims analytics platform, network management and additional risk-taking capabilities to Amedisys' range of home-based services
- 06/30/2021
|
DVA or AMED: Which Is the Better Value Stock Right Now?
- DVA vs. AMED: Which Stock Is the Better Value Option?
- 06/21/2021
|
DVA vs. AMED: Which Stock Is the Better Value Option?
- DVA vs. AMED: Which Stock Is the Better Value Option?
- 06/04/2021
|
These are Wall Street's top analysts favorite stocks heading into June
- TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Deere & Advanced Micro Devices.
- 05/30/2021
|
DVA vs. AMED: Which Stock Should Value Investors Buy Now?
- DVA vs. AMED: Which Stock Is the Better Value Option?
- 05/19/2021
|
Here's Why You Should Buy Amedisys (AMED) Stock Now
- Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.
- 05/13/2021
|
Amedisys (AMED) to Buy VNA Hospice, Home Health, Expand in NE
- The acquisition is going to expand Amedisys' (AMED) presence in Omaha and Council Bluffs' healthcare communities.
- 05/12/2021
|
Amedisys to Present at the 2021 RBC Capital Markets Global Healthcare Conference
- BATON ROUGE, La., May 10, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, and Chris Gerard, President and Chief Operating Officer, will present at the 2021 RBC Capital Markets Healthcare Conference on Tuesday, May 18, 2021.
- 05/10/2021
|
Amedisys to Open Randolph County Home Health Care Center
- BATON ROUGE, La., May 03, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice and personal care, has closed on its acquisition of regulatory assets that allow the Company to conduct home health care operations in Randolph County, N.C.
- 05/03/2021
|
Amedisys, Inc. (AMED) CEO Paul Kusserow on Q1 2021 Results - Earnings Call Transcript
- Amedisys, Inc. (AMED) CEO Paul Kusserow on Q1 2021 Results - Earnings Call Transcript
- 05/02/2021
|
Amedisys and Sound Physicians to Launch “Home Health Advanced” Pilot Program
- BATON ROUGE, La., April 27, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, in collaboration with Sound Physicians, a leading physician practice partner to health systems and plans, physician groups and post-acute providers, will launch the Home Health Advanced Program in the southeastern United States. The program is part of both Amedisys' and Sound Physicians' efforts to provide the highest quality care to patients in their home upon their discharge from an acute setting.
- 04/27/2021
|
Earnings Outlook For Amedisys
- Amedisys (NASDAQ:AMED) announces its next round of earnings this Wednesday, April 28. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.
- 04/27/2021
|
Amedisys (AMED) to Report Q1 Earnings: What's in Store?
- Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.
- 04/21/2021
|
Agape Care Group Appoints Carry vandenMaagdenberg as Its Chief Technology and Innovation Officer and Matt Winer to Chief Operations Officer Post
- SPARTANBURG, S.C.--(BUSINESS WIRE)-- #hospice--Agape Care Group Appoints Carry vandenMaagdenberg as Its Chief Technology and Innovation Officer and Matt Winer to Chief Operations Officer Post
- 04/16/2021
|
Amedisys (AMED) Inks Deal to Extend Home Health Care Operations
- Amedisys' (AMED) new agreement to acquire Randolph Country regulatory assets will broaden the company's footprint in the Home Health care market.
- 04/15/2021
|
Amedisys Announces First Quarter 2021 Earnings Release and Conference Call Date
- BATON ROUGE, La., April 14, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, will report results for the first quarter ended March 31, 2021, after the market closes on April 28, 2021. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on April 29, 2021.
- 04/14/2021
|
Amedisys to Acquire Randolph County Home Health Regulatory Asset
- BATON ROUGE, La., April 14, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire regulatory assets that allow the Company to conduct home health care operations in Randolph County, N.C.
- 04/14/2021
|
Biden Chips in $400B for Home Healthcare: Stocks to Watch
- Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.
- 04/01/2021
|
Amedisys: Growing Into Its Valuation
- Amedisys delivers another strong quarter despite regulatory shifts and COVID-19-related headwinds.
- 03/16/2021
|
Amedisys to Present at Two Virtual Investor Conferences
- BATON ROUGE, La., March 01, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, Chief Executive Officer, will present at both the 42nd Annual Raymond James Institutional Investors Conference and the Barclays Global Healthcare Conference.
- 03/01/2021
|
Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2020 Results - Earnings Call Transcript
- Amedisys, Inc. (AMED) CEO Paul Kusserow on Q4 2020 Results - Earnings Call Transcript
- 02/26/2021
|
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
- Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.
- 02/25/2021
|
Amedisys: Q4 Earnings Insights
- Shares of Amedisys (NASDAQ:AMED) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 58.51% over the past year to $1.49, which beat the estimate of $1.47.
- 02/24/2021
|
Amedisys Announces Two Executive Promotions
- Christopher Gerard named President and Chief Operating Officer and Scott Ginn named Executive Vice President and Chief Financial Officer
- 02/24/2021
|
Preview: Amedisys's Earnings
- On Wednesday, February 24, Amedisys (NASDAQ:AMED) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
- 02/23/2021
|
Is a Surprise Coming for Amedisys (AMED) This Earnings Season?
- Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/23/2021
|
Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?
- Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 02/10/2021
|
Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Date
- BATON ROUGE, La., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the fourth quarter and year ended December 31, 2020, after the market closes on February 24, 2021. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on February 25, 2021.
- 02/09/2021
|
7 Healthy Medical Stocks to Buy
- Some medical stocks gained momentum because of the pandemic, while others focus on high-reward challenges like cancer treatment. The post 7 Healthy Medical Stocks to Buy appeared first on InvestorPlace.
- 02/09/2021
|
3 Biggest MedTech Trends to Watch in 2021 for Better Returns
- Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.
- 01/20/2021
|
What Makes Amedisys (AMED) a Strong Momentum Stock: Buy Now?
- Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/05/2021
|
Amedisys to Present at the 39th Annual J.P. Morgan Healthcare Conference
- BATON ROUGE, La., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021.
- 12/30/2020
|
Amedisys Board of Directors Authorizes $100 million Stock Repurchase Program
- BATON ROUGE, La., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America's leading independent home health, hospice and personal care company, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2021.
- 12/23/2020
|
Amedisys (AMED) Down 5.5% Since Last Earnings Report: Can It Rebound?
- Amedisys (AMED) reported earnings 30 days ago. What's next for the stock?
- 11/27/2020
|
Amedisys to Present at the Jefferies Virtual London Healthcare Conference
- BATON ROUGE, La., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020.
- 11/16/2020
|
Amedisys to Present at the Stephens Annual Investment Conference 2020
- BATON ROUGE, La., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the Stephens Annual Investment Conference 2020 on Thursday, November 19, 2020.
- 11/10/2020
|
Amedisys to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
- BATON ROUGE, La., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020.
- 11/05/2020
|
Amedisys, Inc.'s (AMED) CEO Paul Kusserow on Q3 2020 Results - Earnings Call Transcript
- Amedisys, Inc.'s (AMED) CEO Paul Kusserow on Q3 2020 Results - Earnings Call Transcript
- 10/29/2020
|
Despite A Q3 Beat The Rally In Amedisys Stock Appears Overdone
- After a 82% rise since the March 16 lows of this year, at the current price of around $249 per share we believe Amedisys stock, a home health and hospice care company, has reached its near-term potential. AMED stock has rallied from $137 to $249 off the recent bottom compared to the S&P.
- 10/29/2020
|
Amedisys: Q3 Earnings Insights
- Shares of Amedisys (NASDAQ:AMED) fell 2.7% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 94.78% year over year to $2.24, which beat the estimate of $1.28.
- 10/28/2020
|
Amedisys Reports Third Quarter 2020 Financial Results - Updates 2020 Guidance
- BATON ROUGE, La., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2020.
- 10/28/2020
|
Vestmark Advisory Solutions Inc. Has $649,000 Position in Amedisys Inc (NASDAQ:AMED)
- Vestmark Advisory Solutions Inc. grew its holdings in Amedisys Inc (NASDAQ:AMED) by 30.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,746 shares of the health services provider’s stock after buying an additional 644 shares during the quarter. Vestmark Advisory Solutions Inc.’s […]
- 10/22/2020
|
Global Home Healthcare Software Markets, 2020-2025: Hospice Software Solutions is Expected to be the Fastest Growing Segment - ResearchAndMarkets.com
|
Financial Contrast: Cancer Treatment (OTCMKTS:CTHZ) and Amedisys (OTCMKTS:AMED)
- Cancer Treatment (OTCMKTS:CTHZ) and Amedisys (NASDAQ:AMED) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings. Institutional & Insider Ownership 89.7% of Amedisys shares are owned by institutional investors. 56.1% of Cancer Treatment […]
- 10/18/2020
|
Exane Derivatives Buys Shares of 364 Amedisys Inc (NASDAQ:AMED)
- Exane Derivatives bought a new stake in Amedisys Inc (NASDAQ:AMED) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 364 shares of the health services provider’s stock, valued at approximately $86,000. A number of other large investors also recently modified their holdings of […]
- 10/08/2020
|
Three Oaks Hospice Selects Hospice Pharmacy Solutions® as PBM Partner
- Three Oaks Hospice has joined Hospice Pharmacy Solutions’ Tru360 program and its national network of community-based pharmacies to improve financial
- 10/08/2020
|
Queen City Hospice Expands to Cleveland
- Queen City Hospice LLC expands to Cleveland where it will serve the Greater Cleveland area as Miracle City Hospice.
- 09/30/2020
|
Hike for Hospice begins Oct. 3
- The monthlong event supports Gosnell Memorial Hospice House.
- 09/24/2020
|
Amedisys (NASDAQ:AMED) Price Target Increased to $260.00 by Analysts at Oppenheimer
- Amedisys (NASDAQ:AMED) had its price objective raised by Oppenheimer from $250.00 to $260.00 in a report issued on Monday, The Fly reports. The firm currently has an outperform rating on the health services provider’s stock. Other equities analysts also recently issued research reports about the company. Raymond James boosted their target price on Amedisys from […]
- 09/22/2020
|
Advisor Group Holdings Inc. Boosts Holdings in Amedisys Inc (NASDAQ:AMED)
- Advisor Group Holdings Inc. grew its holdings in Amedisys Inc (NASDAQ:AMED) by 2.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,154 shares of the health services provider’s stock after purchasing an additional 333 shares during the quarter. Advisor Group Holdings Inc.’s […]
- 09/17/2020
|
Jane Margolin Named Hospice Pharmacy Solutions® President
- Hospice Pharmacy Solutions (HPS) is pleased to announce the appointment of Jane Margolin as the organization’s new president.
- 09/14/2020
|
Amedisys Inc (NASDAQ:AMED) CFO Scott G. Ginn Sells 975 Shares
- Amedisys Inc (NASDAQ:AMED) CFO Scott G. Ginn sold 975 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $236.44, for a total transaction of $230,529.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Shares […]
- 09/10/2020
|
Bank of Montreal Can Sells 10,170 Shares of Amedisys Inc (NASDAQ:AMED)
- Bank of Montreal Can trimmed its position in shares of Amedisys Inc (NASDAQ:AMED) by 30.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,045 shares of the health services provider’s stock after selling 10,170 shares during the period. Bank of Montreal Can […]
- 09/10/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/06/2020
|
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/05/2020
|
Amedisys Inc (NASDAQ:AMED) Shares Bought by PNC Financial Services Group Inc.
- PNC Financial Services Group Inc. grew its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 12.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,959 shares of the health services provider’s stock after purchasing an additional 876 shares during the […]
- 08/26/2020
|
Police shoot, kill Black man outside store in Louisiana
- The mother of a man shot to death by police in Louisiana says her son was intelligent, shy and had sought therapy for social anxiety
- 08/23/2020
|
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
- Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
- 08/17/2020
|
Are Strong Financial Prospects The Force That Is Driving The Momentum In Amedisys, Inc.'s NASDAQ:AMED) Stock?
- Amedisys' (NASDAQ:AMED) stock is up by a considerable 31% over the past three months. Since the market usually pay for...
- 08/07/2020
|
Exxon Baton Rouge refinery union to seek talks over 401K change: sources
- Exxon Baton Rouge refinery union to seek talks over 401K change: sources
- 08/07/2020
|
BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana
- BioLife Plasma Services announces opening of first plasma collection center in Louisiana.
- 08/06/2020
|
Stocks Showing Rising Market Leadership: Addus Homecare Earns 82 RS Rating
- On Tuesday, Addus Homecare earned a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
- 08/04/2020
|
Were Hedge Funds Right About Souring On Amedisys Inc (AMED)?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 08/03/2020
|
Nisa Investment Advisors LLC Cuts Stake in Amedisys Inc (NASDAQ:AMED)
- Nisa Investment Advisors LLC cut its position in Amedisys Inc (NASDAQ:AMED) by 1.2% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 15,240 shares of the health services provider’s stock after selling 180 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Amedisys were worth $3,026,000 as of its most recent SEC […]
- 08/01/2020
|
Trane Stock: a Very Cool Pick
- A new emphasis on air quality, spawned by the Covid-19 pandemic, is boosting the HVAC company’s outlook. Also, Wall Street opinions on Texas Instruments, Horizon Technology Finance, Boeing, Amedisys, and Kadant.
- 08/01/2020
|
AMEDISYS Inc (AMED) Q2 2020 Earnings Call Transcript
- AMED earnings call for the period ending June 30, 2020.
- 07/29/2020
|
Amedisys, Inc. (AMED) CEO Paul Kusserow on Q2 2020 Results - Earnings Call Transcript
- Amedisys, Inc. (NASDAQ:AMED) Q2 2020 Earnings Conference Call July 29, 2020 11:00 AM ET Company Participants Nick Muscato - Vice President of Strategic Finance Paul Kusserow - President & Chief Executive Officer Scott Ginn - Chief Financial Officer Chris Gerard - Chief Operating Officer Conference Call Participants Brian Tanquilut - Jefferies Matt Larew - William Blair A.J.
- 07/29/2020
|
Amedisys, Inc. 2020 Q2 - Results - Earnings Call Presentation
- The following slide deck was published by Amedisys, Inc. in conjunction with their 2020 Q2 earnings call..
- 07/29/2020
|
Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2
- Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.
- 07/29/2020
|
Recap: Amedisys Q2 Earnings
- Shares of Amedisys (NASDAQ:AMED) were flat in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 10.74% over the past year to $1.34, which beat the estimate of $0.81.Revenue of $485,059,000 decreased by 1.61% year over year, which beat the estimate of $469,130,000.Outlook The upcoming fiscal year's EPS expected to be between $4.84 and $5.06.View more earnings on AMEDThe upcoming fiscal year's revenue expected to be between $2,040,000,000 and $2,070,000,000.Price Action 52-week high: $221.8852-week low: $121.00Price action over last quarter: Up 25.04%Company Profile Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patient's homes throughout the United States. The Hospice segment operates many centers designed to provide comfort and support for terminally ill patients. The Personal Care Segment provides individuals with assistance in the daily living activities. A majority of the company's revenue is derived from the Home Health segment. Additionally, the Hospice segment accounts for a substantial amount of revenue, while the Personal Care segment makes up for the small remaining revenue.See more from Benzinga * Earnings Scheduled For July 28, 2020 * Stocks That Hit 52-Week Highs On Monday * Benzinga's Top Upgrades, Downgrades For June 18, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/28/2020
|
Amedisys (AMED) Surpasses Q2 Earnings and Revenue Estimates
- Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2020
|
Amedisys Reports Second Quarter 2020 Financial Results - Reissues 2020 Guidance
- BATON ROUGE, La., July 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month period ended June 30, 2020. Three-Month Periods Ended June 30, 2020 and 2019 * Net service revenue decreased $8.0 million to $485.0 million compared to $493.0 million in 2019. * Net income attributable to Amedisys, Inc. of $34.7 million compared to $33.7 million in 2019. * Net income attributable to Amedisys, Inc. per diluted share of $1.04 compared to $1.02 in 2019.Adjusted Quarterly Results* * Adjusted EBITDA of $66.4 million compared to $61.4 million in 2019. * Adjusted net service revenue of $485.0 million compared to $498.5 million in 2019. * Adjusted net income attributable to Amedisys, Inc. of $44.5 million compared to $39.9 million in 2019. * Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.34 compared to $1.21 in 2019.Six-Month Periods Ended June 30, 2020 and 2019 * Net service revenue increased $16.4 million to $976.7 million compared to $960.3 million in 2019. * Net income attributable to Amedisys, Inc. of $66.5 million compared to $65.0 million in 2019. * Net income attributable to Amedisys, Inc. per diluted share of $2.00 compared to $1.98 in 2019.Adjusted Year to Date Results* * Adjusted EBITDA of $119.7 million compared to $116.2 million in 2019. * Adjusted net service revenue of $976.7 million compared to $966.3 million in 2019. * Adjusted net income attributable to Amedisys, Inc. of $79.3 million compared to $76.3 million in 2019. * Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.39 compared to $2.32 in 2019.* See pages 13-15 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.Paul B. Kusserow, President and Chief Executive Officer stated, “I am very proud of our second quarter results which have allowed us to reissue our full year 2020 guidance ranges, but once again, more proud of our employees that delivered these results during such a momentous and unprecedented time in our nation’s history. Our front-line heroes continue to provide the highest quality care to our patients, wherever they call home even in the face of this Public Health Emergency. They have adapted to our COVID-19 policies and procedures, utilized PPE to protect both themselves and our patients, quickly implemented telehealth for additional patient touch points and have gone above and beyond to be great partners to our referral sources. The pandemic continues to highlight the importance of caring for people in their homes, wherever they call home, and as such has positioned Amedisys for continued growth in the future. A special thank you to all our essential healthcare workers - you are true heroes and none of this would be possible without you.”2020 Guidance * Net service revenue is anticipated to be in the range of $2.040 billion to $2.070 billion. * Adjusted EBITDA is anticipated to be in the range of $245 million to $255 million. * Adjusted diluted earnings per share is anticipated to be in the range of $4.84 to $5.06 based on an estimated 33.4 million shares outstanding.This guidance excludes the effects of any future acquisitions, if any are made.We urge caution in considering the current trends and 2020 guidance disclosed in this press release. The home health, hospice and personal care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com. Earnings Call and Webcast Information Amedisys will host a conference call on Wednesday, July 29, 2020, at 11:00 a.m. ET to discuss its second quarter results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through August 29, 2020 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID 13706583.A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.Non-GAAP Financial Measures This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted other operating income, defined as other operating income excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.Additional information Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering our patients to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 21,000 employees in 526 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.Forward-Looking Statements When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein.
- 07/28/2020
|
Why Earnings Season Could Be Great for Amedisys (AMED)
- Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 07/27/2020
|
Stocks To Watch With Earnings On Deck: Amedisys
- Amedisys (AMED) is expected to report earnings on Jul. 28. Amedisys now trading 2% below the 218.54 buy point from a fourth-stage consolidation that it cleared earlier. Understand that it's risky to buy any stock just before it reports. You can reduce your risk by waiting to see the actual numbers and the market's reaction. Looking For The Best Stocks...
- 07/24/2020
|
Amedisys (AMED) Expected to Beat Earnings Estimates: Should You Buy?
- Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/21/2020
|
Amedisys Rides on Coronavirus-Led Business Amid Cost Woes
- Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.
- 07/20/2020
|
Envestnet Asset Management Inc. Increases Stock Position in Amedisys Inc (NASDAQ:AMED)
- Envestnet Asset Management Inc. increased its stake in shares of Amedisys Inc (NASDAQ:AMED) by 5.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 41,486 shares of the health services provider’s stock after buying an additional 2,216 shares during the period. Envestnet Asset Management Inc. owned […]
- 07/17/2020
|
Amedisys Announces Second Quarter Earnings Release and Conference Call Date
- BATON ROUGE, La., July 16, 2020 -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the second quarter ended June 30, 2020, after the market.
- 07/16/2020
|
Tradebe Expanding Technical Services in the Gulf Coast Region
- Tradebe is expanding its' services offerings in the Gulf Coast region centered around its Saraland, AL location.
- 07/16/2020
|
Why the Earnings Surprise Streak Could Continue for Amedisys (AMED)
- Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/14/2020
|
State Street Corp Buys 9,226 Shares of Amedisys Inc (NASDAQ:AMED)
- State Street Corp grew its stake in shares of Amedisys Inc (NASDAQ:AMED) by 0.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,015,219 shares of the health services provider’s stock after acquiring an additional 9,226 shares during the quarter. State Street Corp […]
- 07/13/2020
|
Lululemon, Fortinet Lead 5 Top Stocks In Or Near Buy Zones
- Lululemon, Fortinet, Inphi, Costco Wholesale and Amedisys are leading stocks to watch, all in or near buy zones.
- 07/11/2020
|
Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks
- The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
- 07/10/2020
|
Analysts Offer Insights on Healthcare Companies: UnitedHealth (NYSE: UNH), Amedisys (NASDAQ: AMED) and Osmotica Pharmaceuticals (NASDAQ: OSMT) - Markets
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on UnitedHealth (UNH –
- 07/10/2020
|
ADUS vs. AMED: Which Stock Is the Better Value Option?
- ADUS vs. AMED: Which Stock Is the Better Value Option?
- 07/09/2020
|
Amedisys Inc (NASDAQ:AMED) Shares Bought by Axa
- Axa raised its stake in Amedisys Inc (NASDAQ:AMED) by 127.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 172,047 shares of the health services provider’s stock after purchasing an additional 96,518 shares during the quarter. Axa’s holdings in Amedisys were […]
- 07/02/2020
|
7 Vice ETFs That Are Bound to Deliver Sinful Returns
- While some might overlook the vice stocks theme, there are reasons to take a closer look. Here are the best vice ETFs to buy.
- 06/29/2020
|
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
- Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.
- 06/23/2020
|
Co Antrim schoolgirl becomes first ever NI Children's Hospice youth ambassador
- Madison was inspired by her friends Gracie and Noah Coates who were diagnosed with a rare condition
- 06/22/2020
|
Co Antrim girl (12) first youth ambassador for NI Children's Hospice
- A 12-year-old Co Antrim girl has become the first youth ambassador for the Northern Ireland Children's Hospice.
- 06/22/2020
|
How April Anthony Made A $700 Million Fortune In One Of The Toughest Corners Of U.S. Healthcare
- Anthony built her home healthcare empire during an industry slump that wiped out nearly a third of her competitors. Now she’s facing her biggest challenge yet with Covid-19.
- 06/22/2020
|
These are the death notices from North Staffordshire this week
- Here are is a list of those to appear in North Staffordshire in the last week
- 06/21/2020
|
Deutsche Bank AG Sells 20,095 Shares of Amedisys Inc (NASDAQ:AMED)
- Deutsche Bank AG cut its position in shares of Amedisys Inc (NASDAQ:AMED) by 37.8% in the first quarter, HoldingsChannel reports. The firm owned 33,132 shares of the health services provider’s stock after selling 20,095 shares during the period. Deutsche Bank AG’s holdings in Amedisys were worth $6,081,000 as of its most recent SEC filing. A […]
- 06/20/2020
|
Should You Avoid Amedisys Inc (AMED)?
- In this article you are going to find out whether hedge funds think Amedisys Inc (NASDAQ:AMED) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among […]
- 06/19/2020
|
Obituary: Warren Titcomb
- LANCASTER, Pa. - Warren Titcomb, 74, died on Saturday, June 13, 2020 after a long illness. Born in Portland, Maine, he ...
- 06/19/2020
|
Amedisys Inc (NASDAQ:AMED) Shares Sold by Legal & General Group Plc
- Legal & General Group Plc reduced its position in Amedisys Inc (NASDAQ:AMED) by 0.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 75,734 shares of the health services provider’s stock after selling 592 shares during the quarter. Legal & General Group Plc owned about 0.23% of Amedisys […]
- 06/19/2020
|
Remembering a generous guy who represented Santa well
- Every year, Bill Jindra brought cheer to people who were hospitalized or under hospice care on Christmas.
- 06/18/2020
|
DGX vs. AMED: Which Stock Is the Better Value Option?
- DGX vs. AMED: Which Stock Is the Better Value Option?
- 06/18/2020
|
Benzinga's Top Upgrades, Downgrades For June 18, 2020
- Upgrades * Goldman Sachs changed the rating for CNO Financial Group Inc (NYSE: CNO) from Neutral to Buy. In the first quarter, CNO Finl Gr showed an EPS of $0.58, compared to $0.41 from the year-ago quarter. The stock has a 52-week-high of $20.93 and a 52-week-low of $8.79. CNO Finl Gr's stock last closed at $14.93 per share. * Credit Suisse changed the rating for Church & Dwight Co Inc (NYSE: CHD) from Neutral to Outperform. For the first quarter, Church & Dwight Co had an EPS of $0.83, compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of $80.99 and a 52-week-low of $47.98. Church & Dwight Co's stock last closed at $75.35 per share. * DA Davidson upgraded the stock for MKS Instruments Inc (NASDAQ: MKSI) from Neutral to Buy. For the first quarter, MKS Instruments had an EPS of $1.54, compared to year-ago quarter EPS of $1.12. The stock has a 52-week-high of $122.30 and a 52-week-low of $66.87. MKS Instruments's stock last closed at $109.75 per share. * For Amedisys Inc (NASDAQ: AMED), Benchmark upgraded the stock from Hold to Buy. For the first quarter, Amedisys had an EPS of $1.05, compared to year-ago quarter EPS of $1.11. The stock has a 52-week-high of $218.44 and a 52-week-low of $115.41. Amedisys's stock last closed at $179.88 per share. * For Cloudflare Inc (NYSE: NET), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. Interestingly, in the first quarter, Cloudflare's EPS was ($0.04). The stock has a 52-week-high of $36.00 and a 52-week-low of $14.50. Cloudflare's stock last closed at $35.81 per share. * RBC Capital upgraded the stock for Paylocity Holding Corp (NASDAQ: PCTY) from Sector Perform to Outperform. For the third quarter, Paylocity Holding had an EPS of $0.83, compared to year-ago quarter EPS of $0.60. The stock has a 52-week-high of $150.73 and a 52-week-low of $66.98. Paylocity Holding's stock last closed at $134.38 per share. * Barclays upgraded the stock for Pinnacle West Capital Corp (NYSE: PNW) from Equal-Weight to Overweight. In the first quarter, Pinnacle West Capital showed an EPS of $0.27, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $105.51 and a 52-week-low of $60.05. Pinnacle West Capital's stock last closed at $76.24 per share. * For Zscaler Inc (NASDAQ: ZS), Morgan Stanley upgraded the stock from Underweight to Equal-Weight. Zscaler earned $0.07 in the third quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $112.73 and a 52-week-low of $35.00. Zscaler's stock last closed at $106.18 per share. Downgrades * For Brighthouse Financial Inc (NASDAQ: BHF), Goldman Sachs downgraded the stock from Buy to Neutral. Brighthouse Financial earned $2.60 in the first quarter, compared to $2.21 in the year-ago quarter. The stock has a 52-week-high of $48.25 and a 52-week-low of $12.05. Brighthouse Financial's stock last closed at $31.90 per share. * Goldman Sachs downgraded the stock for Principal Financial Group Inc (NASDAQ: PFG) from Neutral to Sell. Interestingly, in the first quarter, Principal Financial Group's EPS was $1.15. The stock has a 52-week-high of $60.81 and a 52-week-low of $23.31. Principal Financial Group's stock last closed at $42.85 per share. * Citigroup changed the rating for Bank OZK (NASDAQ: OZK) from Buy to Neutral. In the first quarter, Bank OZK showed an EPS of $0.09, compared to $0.86 from the year-ago quarter. The stock has a 52-week-high of $31.76 and a 52-week-low of $14.20. Bank OZK's stock last closed at $24.30 per share. * Wells Fargo changed the rating for Accenture PLC (NYSE: ACN) from Overweight to Equal-Weight. Accenture earned $1.91 in the second quarter, compared to $1.73 in the year-ago quarter. The stock has a 52-week-high of $216.39 and a 52-week-low of $137.15. Accenture's stock last closed at $205.14 per share. * DZ Bank changed the rating for American Express Co (NYSE: AXP) from Buy to Hold. In the first quarter, American Express showed an EPS of $1.98, compared to $2.01 from the year-ago quarter. The stock has a 52-week-high of $138.13 and a 52-week-low of $67.00. American Express's stock last closed at $103.96 per share. * Berenberg changed the rating for Carnival Corp (NYSE: CCL) from Hold to Sell. For the second quarter, Carnival had an EPS of ($3.30), compared to year-ago quarter EPS of $0.66. The stock has a 52-week-high of $53.34 and a 52-week-low of $7.80. Carnival's stock last closed at $19.08 per share. * For DHT Holdings Inc (NYSE: DHT), Stifel downgraded the stock from Buy to Hold. In the first quarter, DHT Holdings showed an EPS of $0.44, compared to $0.12 from the year-ago quarter. The stock has a 52-week-high of $8.83 and a 52-week-low of $4.77. DHT Holdings's stock last closed at $5.54 per share. Initiations * Northland Capital Markets initiated coverage on Alphatec Holdings Inc (NASDAQ: ATEC) with an Outperform rating. The price target for Alphatec Holdings is set at $9.00. In the first quarter, Alphatec Holdings showed an EPS of ($0.33), compared to ($0.29) from the year-ago quarter. The stock has a 52-week-high of $7.93 and a 52-week-low of $2.19. Alphatec Holdings's stock last closed at $4.88 per share. * With a rating of Buy, SunTrust Robinson Humphrey initiated coverage on Editas Medicine Inc (NASDAQ: EDIT). The price target is set at $45.00 for Editas Medicine. For the first quarter, Editas Medicine had an EPS of ($0.69), compared to year-ago quarter EPS of ($0.60). The stock has a 52-week-high of $34.37 and a 52-week-low of $14.01. Editas Medicine's stock last closed at $29.89 per share. * Janney Capital initiated coverage on Invitation Homes Inc (NYSE: INVH) with a Buy rating. The price target for Invitation Homes is set at $34.00. For the first quarter, Invitation Homes had an EPS of $0.34, compared to year-ago quarter EPS of $0.33. The stock has a 52-week-high of $32.70 and a 52-week-low of $15.64. Invitation Homes's stock last closed at $28.41 per share. * Baird initiated coverage on CoStar Group Inc (NASDAQ: CSGP) with an Outperform rating. The price target for CoStar Gr is set at $755.00. CoStar Gr earned $2.44 in the first quarter, compared to $2.53 in the year-ago quarter. The stock has a 52-week-high of $746.70 and a 52-week-low of $500.24. CoStar Gr's stock last closed at $689.44 per share. * Stifel initiated coverage on Health Catalyst Inc (NASDAQ: HCAT) with a Buy rating. The price target for Health Catalyst is set at $36.00. In the first quarter, Health Catalyst earned ($0.16). The stock has a 52-week-high of $49.85 and a 52-week-low of $17.48. Health Catalyst's stock last closed at $29.69 per share. * RBC Capital initiated coverage on Tyler Technologies Inc (NYSE: TYL) with an Outperform rating. The price target for Tyler Technologies is set at $375.00. For the first quarter, Tyler Technologies had an EPS of $1.25, compared to year-ago quarter EPS of $1.22. The stock has a 52-week-high of $382.92 and a 52-week-low of $210.80. Tyler Technologies's stock last closed at $339.17 per share. * With a rating of Buy, Mizuho initiated coverage on Neoleukin Therapeutics Inc (NASDAQ: NLTX). The price target is set at $21.00 for Neoleukin Therapeutics. Neoleukin Therapeutics earned ($0.18) in the first quarter, compared to ($0.09) in the year-ago quarter. The stock has a 52-week-high of $15.35 and a 52-week-low of $2.53. Neoleukin Therapeutics's stock last closed at $13.52 per share. * MKM Partners initiated coverage on QEP Resources Inc (NYSE: QEP) with a Buy rating. The price target for QEP Resources is set at $3.00. In the first quarter, QEP Resources showed an EPS of $0.21, compared to $0.15 from the year-ago quarter. The stock has a 52-week-high of $7.42 and a 52-week-low of $0.26. QEP Resources's stock last closed at $1.60 per share.See more from Benzinga * 14 Energy Stocks Moving In Thursday's Pre-Market Session * Kroger: Q1 Earnings Insights * 16 Financial Services Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/18/2020
|
Amedisys to Present at the BMO 2020 Prescriptions for Success Healthcare Conference | MarketScreener
|
Amedisys to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
- BATON ROUGE, La., June 17, 2020 -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B..
- 06/17/2020
|
God, cancer and Byron Hayward - the man who replaced Shaun Edwards tells all
- Wales' new defence coach found God and changed his life.
- 06/17/2020
|
Amedisys Inc (NASDAQ:AMED) Shares Sold by Franklin Resources Inc.
- Franklin Resources Inc. lessened its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 17.8% in the first quarter, according to its most recent filing with the SEC. The firm owned 1,157 shares of the health services provider’s stock after selling 251 shares during the quarter. Franklin Resources Inc.’s holdings in Amedisys were worth $212,000 as […]
- 06/17/2020
|
NI sisters complete 100 miles of exercise for NI Hospice
- The youngsters have already smashed their target
- 06/13/2020
|
The 2 Mid-Cap Stocks Down Since Market Bottom (NYSEARCA:MDY)
- Since the market lows in late March, the S&P MidCap 400 Index is up 57%, outpacing a record rally in the S&P 500. Remarkably, only two of the 400 constituents i
- 06/10/2020
|
Obituary: Dawn Perry Carter
- NEW LONDON, N.H. - Dawn Perry Carter of New London, New Hampshire died on June 8, 2020 at home with her ...
- 06/10/2020
|
The North Belfast woman who has given 34 years of service to NI Hospice
- "The people I met dealt with what they had to deal with with so much dignity and courage"
- 06/07/2020
|
Amedisys (AMED) Up 2.5% Since Last Earnings Report: Can It Continue?
- Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 06/05/2020
|
Why Coronavirus Test Firms Are Among 4 Key Health Care Stocks
- The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
- 06/05/2020
|
Amedisys to Present at the 40th Annual William Blair Growth Stock Conference
- BATON ROUGE, La., June 05, 2020 -- Amedisys, Inc. (NASDAQ: AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B..
- 06/05/2020
|
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
- Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
- 06/03/2020
|
Amedisys Completes The Acquisition Of AseraCare Hospice For A $235M In Cash
|
Amedisys Completes Acquisition of AseraCare Hospice
- Amedisys, Inc. (AMED), a leading provider of home health, hospice and personal care, announced today that, through one of its wholly owned subsidiaries, it has closed on its acquisition of Homecare Preferred Choice, Inc., doing business as AseraCare Hospice (“AseraCare Hospice” or “AseraCare”), a national hospice care provider with an executive office in Plano, Texas and administrative support center in Fort Smith, Arkansas. Under the terms of the agreement, Amedisys acquired 100 percent of the ownership interests in AseraCare Hospice for a cash purchase price of $235 million, which is inclusive of a $32 million tax asset bringing the net purchase price to $203 million.
- 06/01/2020
|
Edited Transcript of AMED earnings conference call or presentation 7-May-20 3:00pm GMT
- Q1 2020 Amedisys Inc Earnings Call
- 06/01/2020
|
Where and when were Leicestershire's first 555 coronavirus deaths
- Detailed data will be scrutinised by councillors this week
- 06/01/2020
|
How people are helping others through the coronavirus outbreak
- If you know of anyone going above and beyond to help keep others stay safe let us know
- 05/29/2020
|
Amedisys to Present at the 2020 Jefferies Virtual Healthcare Conference
- Amedisys, Inc. (AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com. Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care.
- 05/28/2020
|
Watch as Antrim GAA club man leaves ICU to applause after eight weeks
- Gerard is a club and committee member of the Kickham GAA club in Creggan and as he left the intensive care ward, we was greeted with applause from the staff in the hospital.
- 05/28/2020
|
CEO Spins The Golden Rule Into Business Gold
- Amedisys CEO Paul Kusserow doesn't try to lead. He aims to serve instead. And in the process he's built a winning company with heart.
- 05/28/2020
|
Amedisys to Present at the —…—… Jefferies Virtual Healthcare Conference
|
SunTrust Robinson Humphrey Maintains Buy on Amedisys, Raises Price Target to $240
|
Fundraiser runs every street in Chester to raise money for hospice
- Nicholas Brooks is supporting the Hospice of the Good Shepherd’s #SaveYourHospice appeal
- 05/20/2020
|
US Post Acute Care Appoints Kevin Henning as Chief Medical Officer
- US Post Acute Care appoints Kevin Henning MD as Chief Medical Officer
- 05/19/2020
|
'Nuneaton has lost its great champion' - tribute to former MP
- Neighbouring MP and Labour Party colleague Mike O'Brien paid tribute to Bill
- 05/18/2020
|
12 health-care stocks that will be winners because of coronavirus-led trends, according to Jefferies
- DEEP DIVE The COVID-19 pandemic has accelerated some health-care trends while opening people’s eyes to others that now seem obvious. Analysts at investment bank Jefferies have listed stocks of companies they argue are likely winners and losers from those trends.
- 05/16/2020
|
Latest virus deaths at care homes, hospices and at home revealed
- Here's the figures for each local authority area
- 05/14/2020
|
Marietta Investment Partners Llc Buys Amedisys Inc, NICE, Yum China Holdings Inc, Sells Stryker ...
|
Amedisys to Present at RBC Capital Markets 2020 Global Healthcare Conference
- Amedisys, Inc. (AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at RBC Capital Markets 2020 Global Healthcare Conference on Tuesday, May 19, 2020. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com. Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care.
- 05/13/2020
|
United Health Foundation Donates $750,000 to Support Pennsylvania’s Home Care, Home Health and Hospice Workers Amid COVID-19 Emergency
- The United Health Foundation has donated $750,000 to provide personal protective equipment (PPE) and support for frontline health care workers fightin
- 05/13/2020
|
12 health-care stocks that will be winners because of coronavirus-led trends, according to Jefferies
- Changes in health services and medical technology will be accelerated by COVID-19.
- 05/12/2020
|
Amedisys to Present at the UBS Virtual Global Healthcare Conference 2020
- Amedisys, Inc. (AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the UBS Global Healthcare Conference 2020 on Monday, May 18, 2020. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com. Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care.
- 05/11/2020
|
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Equity Residential : Evercore ISI raises to in-line from underperform
* Fiserv Inc : Keybanc raises target price to $115 from $108
* GTT Communications Inc : SunTrust Robinson cuts to hold from buy
* UDR Inc : Evercore ISI raises to in-line from underperform
Following is a summary of research actions on U.S. companies reported by Reuters on Monday.
Stock entries are in alphabetical order.
* Abbvie Inc : SVB Leerink raises price target to $122 from $107
* Accelerate Diagnostics Inc : Piper Sandler cuts target price to $14 from $16
* Acushnet Holdings Corp : Compass Point raises TP to $22.25 from $21.50
* Acushnet Holdings Corp : Keybanc raises target price to $31 from $28
* Acushnet Holdings Corp : Stephens raises target price to $27 from $24
* Advance Auto Parts Inc : UBS raises target price to $140 from $135
* AIG : UBS cuts target price to $45 from $49
* Air Lease Corp : Deutsche Bank cuts target price to $36 from $45
* Air Lease Corp : Stephens raises target price to $36 from $30
* Airgain Inc : Northland Capital Markets raises target price to $23
* Alarm.Com Holdings Inc : Credit Suisse cuts target price to $62 from $64
* Albemarle Corp : RBC raises target price to $66 from $64
* Albemarle Corp : SunTrust Robinson cuts target price to $65 from $90
* Allegiant Travel Co : Evercore ISI cuts target price to $95 from $100
* Allscripts Healthcare Solutions : Canaccord Genuity cuts TP to $11 from $13
* Amdocs Ltd : Citigroup cuts price target to $76 from $83
* Amedisys Inc : Raymond James cuts price target to $210 from $225
* Amedisys Inc : UBS cuts target price to $190 from $208
* American Axle & Manufacturing Holdings : Citigroup raises TP to $7.5 from $6
* American Axle & Manufacturing Holdings : RBC raises target price to $7 from $5
* American Homes 4 Rent : Evercore ISI raises target price to $27 from $25
* Ameriprise Financial Inc : RBC raises target price to $155 from $145
* Amerisourcebergen Corp : Deutsche Bank raises target price to $98 from $93
* Amphastar Pharmaceuticals Inc : BMO raises price target to $21 from $20
* Angi Homeservices Inc : Citigroup raises price target to $10 from $6.5
* Aon Plc : Citigroup cuts price target to $230 from $240
* Aon Plc : KBW raises target price to $192 from $184
* Aon Plc : UBS cuts target price to $197 from $202
* Apache Corp : CFRA cuts to sell from hold; raises price target to $9
* Apache Corp : MKM Partners cuts target price by $1 to $19
* Aptiv Plc : Benchmark cuts price target to $87 from $90
* Arch Capital Group Ltd : UBS cuts target price to $39 from $43
* Atara Biotherapeutics Inc : Jefferies cuts target price to $11 from $13
* Athene Holding Ltd : BMO cuts price target to $60 from $63
* Atricure Inc : BTIG raises target price to $56 from $45
* Atricure Inc : Needham raises target price to $63 from $49
* Atricure Inc : Oppenheimer raises price target to $52 from $45
* Atricure Inc : SVB Leerink raises price target to $55 from $50
* Autonation Inc : CFRA cuts price target by $10 to $50
* Avalonbay Communities Inc : Evercore ISI cuts target price to $181 from $189
* Avista Corp : Guggenheim cuts target price to $38 from $39
* Bain Capital Specialty Finance : Citigroup raises price target to $10 from $7.5
* Ball Corp : Citigroup cuts price target to $86 from $89
* Ball Corp : Northland Capital Markets cuts target price to $80
* Baudax Bio Inc : Oppenheimer cuts price target to $14 from $16
* Bellring Brands Inc : Stifel cuts target price to $23 from $25
* BJ's Restaurants Inc : Deutsche Bank raises target price to $27 from $26
* Bloomin' Brands Inc : BMO raises price target to $10 from $9
* Bloomin' Brands Inc : Deutsche Bank raises target price to $15 from $14
* Bloomin' Brands Inc : Guggenheim raises target price to $15 from $11
* Bloomin' Brands Inc : Raymond James cuts target price to $14 from $15
* BP Midstream Partners LP : Mizuho raises target price to $14 from $13
* Broadridge Financial Solutions : Piper Sandler cuts TP to $120 from $124
* Broadridge Financial Solutions : Rosenblatt Securities ups TP to $115 from $101
* Brookfield Infrastructure Partners LP : BMO raises price target to $46 from $45
* Brookfield Infrastructure Partners LP : Scotiabank cuts Tp to $50 from $51
* Brookfield Property Partners LP : Canaccord Genuity cuts TP to $12 from $13
* Brookfield Property Partners LP : CIBC cuts target price to $18 from $20.50
* Brookfield Property Partners LP : RBC cuts target price to $18 from $22
* Bruker Corp : BTIG cuts price target to $50 from $57
* Cabot Oil & Gas Corp : Tudor Pickering Holt cuts to hold from buy
* Calithera Biosciences Inc : Citigroup raises price target to $10 from $7
* Callaway Golf Co : >: Compass Point cuts target price to $17.50 from $20
* Callaway Golf Co : Compass Point cuts target price to $17.50 from $20
* Camden Property Trust : Evercore ISI cuts target price to $98 from $102
* Camden Property Trust : Stifel raises target price to $96 from $91
* Cardtronics Plc : D.A. Davidson cuts target price to $34 from $40
* Cardtronics Plc : SunTrust Robinson raises target price to $29 from $23
* Cargurus Inc : RBC raises target price to $25 from $22
* Carnival : HSBC raises to buy from hold; cuts target price to $15.9 from $45.3
* Carrier Global Corp : Citigroup raises price target to $20 from $17
* Carvana Co : Oppenheimer raises price target to $127 from $95
* Carvana Co : Oppenheimer raises target price to $127 from $95
* Casella Waste Systems Inc : Jefferies raises target price to $56 from $52
* Casella Waste Systems Inc : Raymond James raises target price to $56 from $49
* Casella Waste Systems Inc : Stifel raises target price to $47 from $45
* Cellectis : Citigroup cuts price target to $15 from $16
* Centurylink Inc : SunTrust Robinson cuts target price to $9 from $10
* Ceridian Hcm Holding Inc : Jefferies raises target price to $65 from $60
* Chevron Corp : Independent Research raises target price to $98 from $90; hold
* CNX Resources Corp : Tudor Pickering Holt cuts to hold from buy
* Cognizant Technology Solutions : Evercore ISI cuts target price to $53 from $55
* Cognizant Technology Solutions Corp : HSBC cuts target price to $56 from $70
* Coherus Biosciences Inc : Citigroup cuts price target to $30 from $31
* Conagra Brands Inc : SunTrust Robinson cuts to hold from buy
* Consolidated Edison Inc : Evercore ISI cuts target price to $85 from $86
* Continental Resources : TD Securities raises target price to $14.50 from $13.50
* Cooper Tire & Rubber Co : JP Morgan cuts target price to $29 from $30
* Corporate Office Properties Trust : SunTrust Robinson raises TP to $28 from $26
* Corteva Inc : RBC raises target price to $31 from $27
* Covanta Holding : Stifel raises to hold from sell; raises TP to $9.50 from $6.50
* Crocs Inc : Piper Sandler raises target price to $28 from $24
* Cross Country Healthcare Inc : BMO cuts price target to $8 from $11
* Cryoport Inc : Stephens raises target price to $23 from $21
* CVR Energy Inc : Credit Suisse raises target price to $19 from $16
* Cytomx Therapeutics Inc : Wedbush raises target price to $16 from $11
* Danaher Corp : Evercore ISI raises target price to $175 from $150
* Danaher Corp : RBC raises target price to $173 from $159
* Datadog Inc : RBC raises target price to $50 from $43
* Dentsply Sirona : Barrington Research cuts to market perform from outperform
* Dentsply Sirona Inc : UBS cuts target price to $44 from $59
* Dicerna Pharmaceuticals : SunTrust Robinson raises target price to $33 from $28
* Diebold Nixdorf Inc : JP Morgan raises target price to $7 from $6
* Diebold Nixdorf Inc : JP Morgan raises to neutral from underweight
* Discovery Inc : Rosenblatt Securities cuts price target to $24 from $27
* Dish Network Corp : RBC cuts target price to $32 from $39
* Domtar : D.A. Davidson cuts to neutral from buy; cuts TP to $26 from $44
* Domtar Corp : Scotiabank cuts target price to $29 from $30
* Domtar Corp : TD Securities raises target price to $26 from $22
* E. W. Scripps Co : Benchmark cuts target price to $15 from $24
* E. W. Scripps Co : Guggenheim raises target price to $8 from $6.50
* Edison Intl.
- 05/11/2020
|
UBS Maintains Neutral on Amedisys, Lowers Price Target to $190
|
Raymond James Maintains Outperform on Amedisys, Lowers Price Target to $210
|
Amedisys, Inc. (AMED) CEO Paul Kusserow on Q1 2020 Results - Earnings Call Transcript
- Amedisys, Inc. (NASDAQ:AMED) Q1 2020 Earnings Conference Call May 07, 2020, 11:00 AM ET Company Participants Nick Muscato - VP of Strategic Finance Paul Kussero
- 05/10/2020
|
Edited Transcript of AMED earnings conference call or presentation 7-May-20 3:00pm GMT
- Q1 2020 Amedisys Inc Earnings Call
- 05/08/2020
|
U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies
- Wall Street securities analysts on Thursday revised their ratings and
price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and
Solaredge Technologies.
HIGHLIGHTS
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Lyft Inc : Piper Sandler cuts to neutral from overweight
* Natera Inc : JP Morgan raises to overweight from neutral
* Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell
* Solaredge Technologies : Canaccord Genuity cuts to hold from buy
Following is a summary of research actions on U.S. companies reported by Reuters on Thursday.
Stock entries are in alphabetical order.
* A. O. Smith Corp : Stephens raises target price to $40 from $37
* Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37
* Acadia Healthcare Company Inc : Deutsche Bank cuts target price to $28 from $32
* Activision Blizzard Inc : Keybanc raises target price to $80 from $68
* Adient Plc : Deutsche Bank raises target price to $20 from $15
* ADMA Biologics Inc : Oppenheimer cuts target price to $7 from $14
* Advanced Energy Industries Inc : Citigroup raises price target to $63 from $40
* Advanced Energy Industries Inc : Cowen and Company raises PT to $58 from $51
* Advanced Energy Industries Inc : D.A. Davidson raises target to $60 from $50
* Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90
* Aerie Pharmaceuticals Inc : H.C. Wainwright cuts target price to $31 from $37
* Aerie Pharmaceuticals Inc : Mizuho cuts target price to $29 from $34
* Aerie Pharmaceuticals Inc : Piper Sandler cuts target price to $35 from $45
* Aerie Pharmaceuticals Inc : SunTrust Robinson cuts price target to $22 from $26
* Agco Corp : Stephens raises target price to $65 from $60
* Air Transport Services Group Inc : Cowen and Company raises PT to $26 from $25
* Albemarle Corp : UBS cuts target price to $90 from $98
* Alexion Pharmaceuticals Inc : BMO cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147
* Alexion Pharmaceuticals Inc : Jefferies cuts price target to $111 from $112
* Alexion Pharmaceuticals Inc : Raymond James cuts target price to $156 from $159
* Alexion Pharmaceuticals Inc : SunTrust Robinson cuts target to $135 from $141
* Alexion Pharmaceuticals Inc : SVB Leerink cuts target price to $150 from $156
* Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100
* Allete Inc : Guggenheim cuts price target to $65 from $70
* Allogene Therapeutics Inc : Jefferies raises target price to $37 from $36
* Allstate Corp : Piper Sandler raises target price to $112 from $108
* Alnylam Pharmaceuticals Inc : Guggenheim raises price target to $166 from $155
* Alnylam Pharmaceuticals Inc : BMO raises target price to $171 from $145
* Alnylam Pharmaceuticals Inc : Jefferies raises price target to $165 from $142
* Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight
* Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133
* Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135
* Alnylam Pharmaceuticals Inc : Oppenheimer raises target price to $162 from $140
* Alnylam Pharmaceuticals Inc : Piper Sandler raises target to $169 from $142
* Alteryx Inc : Citigroup cuts price target to $147 from $160
* Alteryx Inc : Cowen and Company cuts target price to $135 from $145
* Alteryx Inc : Needham cuts target price to $140 from $152
* Alteryx Inc : Wedbush cuts price target to $138 from $146
* Amedisys Inc : Benchmark cuts to hold rating
* Ameriprise Financial Inc : Evercore ISI raises target price to $139 from $136
* Ametek Inc : Berenberg raises target price to $93 from $86
* Ametek Inc : Stephens cuts target price to $92 from $94
* Anaptysbio Inc : Credit Suisse raises target price to $16 from $14
* Apache Corp : Credit Suisse raises target price to $10 from $4
* Aptiv Plc : Deutsche Bank raises target price to $75 from $59
* Arcus Biosciences Inc : Wedbush raises target price to $40 from $26
* Ares Capital Corp : BMO cuts target price by $5 to $16
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Ares Management Corp : BMO raises target price to $40 from $30
* Ares Management Corp : Credit Suisse raises target price to $40 from $38
* Ares Management Corp : Jefferies raises target price to $42 from $39
* Ares Management Corp : KBW raises target price to $45 from $44
* ASGN Inc : Jefferies raises target price to $54 from $31
* Ashland Global Holdings Inc : Deutsche Bank raises target price to $70 from $65
* Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68
* Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight
* Ashland Global Holdings Inc. : SunTrust Robinson cuts price target to $75 from $87
* Aspen Technology Inc : Benchmark cuts target price to $130
* Aspen Technology Inc : Keybanc raises target price to $120 from $110
* Assetmark Financial Holdings Inc : BMO cuts target price to $23 from $26
* Assurant Inc : SunTrust Robinson cuts price target to $145 from $155
* Astronics Corp : Canaccord Genuity cuts target price to $10 from $14
* Astronics Corp : SunTrust Robinson cuts price target to $6 from $7
* Atkore International Group Inc : Citigroup raises price target to $26 from $24
* Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12
* Avanos Medical Inc : Berenberg raises target price to $33 from $30
* Avanos Medical Inc : Stephens raises target price to $38 from $30
* Axalta Coating Systems Ltd : Citigroup raises price target to $21 from $18
* Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29
* Axalta Coating Systems Ltd : Jefferies raises target price to $18 from $15
* Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23
* Axcelis Technologies Inc : D.A. Davidson raises price target to $25 from $20
* Axcella Health Inc : BTIG raises target price to $12 from $10
* Axogen Inc : Canaccord Genuity cuts target price to $12 from $22
* Axogen Inc : Jefferies cuts target price to $21 from $30
* Bank of N.T. Butterfield & Son Ltd : Citigroup raises target to $21 from $15
* Barrett Business Services Inc : Barrington Research raises PT to $52 from $48
* Barrick Gold Corp : Deutsche Bank raises target price to $34 from $25
* Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35
* Bio Rad Laboratories Inc : Citigroup raises price target to $525 from $480
* Bio Rad Laboratories Inc : Jefferies raises target price to $525 from $500
* Biocryst Pharmaceuticals Inc : Jefferies raises price target to $9 from $8
* Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8
* Biotelemetry Inc : Benchmark cuts target price to $52 from $55
* Black Knight Inc : KBW raises target price to $70 from $68
* Black Knight Inc : Stephens raises target price to $88 from $84
* Black Knight Inc : Wedbush raises target price to $70 from $66
* Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5
* Blackbaud Inc : Evercore ISI cuts target price to $48 from $55
* Blucora Inc : Benchmark cuts price target to $25 from $37
* BMC stock Holdings Inc : Stephens raises target price to $25 from $22
* BMC stock Holdings Inc : SunTrust Robinson raises price target to $26 from $22
* BorgWarner Inc : Jefferies raises target price to $33 from $30
* BorgWarner Inc : JP Morgan raises price target to $35 from $32
* BorgWarner Inc : Oppenheimer cuts target price to $44 from $45
* BorgWarner Inc : RBC raises target price to $31 from $29
* Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.
- 05/07/2020
|
Amedisys Inc (AMED) CFO Scott G Ginn Sold $–.6 million of Shares
|
Amedisys (AMED) Beats Q1 Earnings Estimates
- Amedisys (AMED) delivered earnings and revenue surprises of 8.25% and -4.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2020
|
Amedisys Q1 EPS $1.050 Beats $0.970 Estimate, Sales $491.685M Miss $505.460M Estimate
|
Amedisys Reports First Quarter 2020 Financial Results
- BATON ROUGE, La., May 06, 2020 -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2020. Three-Month Periods Ended.
- 05/06/2020
|
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
- Interest Coverage Ratio suggests how many times the interest could be paid from earnings and gauges the margin of safety a firm has for paying interest.
- 05/05/2020
|
A Look At The Intrinsic Value Of Amedisys, Inc. (NASDAQ:AMED)
- Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Amedisys, Inc...
- 05/05/2020
|
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio
|
Zacks.com featured highlights include: NEE, FNV, AMED, ATO and COST
|
Deeply missed and loved always - these are the death notices from this week
- The death announcements published in The Sentinel this week
- 05/03/2020
|
Bet on These 5 Low Leverage Stocks to Avoid Huge Losses
- With the earnings season in full swing, the real challenge for an investor is determining whether an organization's debt level is sustainable.
- 05/01/2020
|
Amedisys Celebrates More Than 8,000 Nurses During National Nurses Month
- Amedisys, Inc. (AMED), one of the nation’s leading home healthcare, hospice and personal care companies, celebrates National Nurses Month by honoring more than 8,000 nurses who call the company home. Traditionally, National Nurses Week begins each year on May 6 and ends on May 12, Florence Nightingale’s birthday. With the World Health Organization declaring 2020 as the Year of the Nurse and Midwife, this celebration has been extended to the entire month.
- 05/01/2020
|
Amedisys Celebrates More Than 8,000 Nurses During National Nurses Month
- BATON ROUGE, La., May 01, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), one of the nation’s leading home healthcare, hospice and personal care...
- 05/01/2020
|
Amedisys Inc (NASDAQ:AMED) Shares Sold by Calamos Advisors LLC
- Calamos Advisors LLC cut its position in Amedisys Inc (NASDAQ:AMED) by 15.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,279 shares of the health services provider’s stock after selling 6,379 shares during the quarter. Calamos Advisors LLC owned 0.11% of […]
- 05/01/2020
|
Amedisys Celebrates More Than 8,……… Nurses During National Nurses Month
|
Russell 2000 Retreats
- The Russell 2000 Index is pulling back today after hitting a major resistance level yesterday.
- 04/30/2020
|
5 Stocks to Buy Now for a W-Shaped Recovery With a Long Recession
- These five stocks could be big winners if the recovery is W-shaped and we and we return to the March lows before turning higher. They also have had substantial insider buying recently, a good sign for investors.
- 04/30/2020
|
Oppenheimer Reaffirms Buy Rating for Amedisys (NASDAQ:AMED)
- Oppenheimer reaffirmed their buy rating on shares of Amedisys (NASDAQ:AMED) in a report released on Monday, AnalystRatings.com reports. Oppenheimer currently has a $215.00 target price on the health services provider’s stock. Other equities research analysts also recently issued research reports about the company. Raymond James upped their price target on Amedisys from $200.00 to $225.00 […]
- 04/30/2020
|
Amedisys Inc Forecasted to Post Q1 2020 Earnings of $0.96 Per Share (NASDAQ:AMED)
- Amedisys Inc (NASDAQ:AMED) – Equities research analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for Amedisys in a research note issued on Tuesday, April 28th. Jefferies Financial Group analyst B. Tanquilut anticipates that the health services provider will earn $0.96 per share for the quarter. Jefferies Financial Group also issued estimates for […]
- 04/30/2020
|
Amedisys to Present at the BofA Securities 2020 Virtual Health Care Conference
- Amedisys, Inc. (AMED), one of America's leading home health, hospice and personal care companies, today announced that Paul B. Kusserow, President and Chief Executive Officer will present at the BofA Securities 2020 Virtual Health Care Conference on Tuesday, May 12, 2020. To access a live webcast of the Amedisys presentation, please log on through our website at http://investors.amedisys.com. Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care.
- 04/29/2020
|
Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline
- Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2020
|
Earnings Preview: Amedisys (AMED) Q1 Earnings Expected to Decline
- Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2020
|
Stocks To Watch With Earnings Approaching: Amedisys
|
10 Stocks to Buy for an Aging Population
- Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.
- 04/28/2020
|
U.S. RESEARCH ROUNDUP- American Tower, Ferrari, Walt Disney
- Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including American Tower, Ferrari and Walt Disney, on Tuesday.
HIGHLIGHTS
* American Tower Corp : Credit Suisse initiates with outperform rating
* CNX Resources Corp : Raymond James raises to outperform from underperform
* Ferrari : Jefferies cuts to underperform rating
* ViacomCBS Inc : RBC initiates with sector perform, $20 target price
* Walt Disney Co : RBC initiates with sector perform, $110 target price
Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday.
Stock entries are in alphabetical order.
* Acadia Realty Trust : SunTrust Robinson starts with hold rating; price target $13
* Aecom : Keybanc raises target price to $45 from $35
* Affiliated Managers Group Inc : Citigroup cuts price target to $66.5 from $70
* Affiliated Managers Group Inc : Credit Suisse raises target price to $57 from $56
* Affiliated Managers Group Inc : Deutsche Bank raises target price to $67 from $63
* Affiliated Managers Group Inc : KBW raises target price to $80 from $75
* Alaska Air Group : Cowen and Company cuts target price to $39 from $45
* AMC Networks Inc : RBC initiates with outperform, $27 target price
* Amedisys Inc : Jefferies raises target price to $225 from $210
* American Eagle Outfitters Inc : RBC cuts target price to $8 from $9
* American Tower Corp : Credit Suisse initiates with $308 target price
* American Tower Corp : Credit Suisse initiates with outperform rating
* Ameris Bancorp : Stephens cuts target price to $28 from $31
* Amkor Technology Inc : Deutsche Bank raises target price to $11 from $10
* Annaly Capital Management Inc : RBC cuts target price to $8 from $11
* Antero Midstream Corp : JP Morgan cuts to underweight from neutral
* Apollo Endosurgery Inc : Piper Sandler cuts target price to $2 from $4.50
* Apollo Endosurgery Inc : Piper Sandler cuts to neutral from overweight
* Arcosa Inc : Susquehanna cuts price target to $48 from $56
* Arcturus Therapeutics Holdings Inc : H.C. Wainwright raises PT to $62 from $26
* Armstrong World Industries Inc : Evercore ISI raises target price to $78 from $77
* Armstrong World Industries Inc : Jefferies cuts price target to $73 from $74
* Armstrong World Industries Inc : SunTrust Robinson cuts PT to $95 from $100
* Assetmark Financial Holdings Inc : JP Morgan cuts target price to $25 from $31
* AT&T Inc : Deutsche Bank cuts target price to $38 from $45
* Autoliv Inc : Citigroup raises price target to $61 from $46
* Avnet Inc : Citigroup cuts price target to $31 from $34
* Avnet Inc : Raymond James cuts target price to $44 from $47
* Axis Capital Holdings Ltd : Deutsche Bank cuts target price to $46 from $52
* Axsome Therapeutics Inc : Cowen and Company raises target price to $135 from $95
* Axsome Therapeutics Inc : Guggenheim raises target price to $200 from $158
* Axsome Therapeutics Inc : H.C. Wainwright raises price target to $210 from $200
* Axsome Therapeutics Inc : SunTrust Robinson raises target price to $200 from $145
* Axsome Therapeutics Inc : SVB Leerink raises target price to $115 from $100
* B&G Foods Inc : Credit Suisse raises price target to $19 from $17
* B&G Foods Inc : Credit Suisse raises to neutral from underperform
* Bank of America : Independent Research cuts PT to $26.00 from $38.50; rating hold
* Bank of America Corp : Oppenheimer raises target price to $36 from $33
* Bank Ozk : SunTrust Robinson raises target price to $22 from $19
* Bankfinancial Corp : D.A. Davidson cuts target price to $9 from $10
* Big Lots Inc : JP Morgan raises target price to $25 from $21
* Boston Properties Inc : JP Morgan cuts target price to $118 from $147
* Boston Properties Inc : Mizuho cuts price target to $105 from $152
* BP Midstream Partners LP : Citigroup cuts price target to $11.5 from $15
* Brandywine Realty Trust : SunTrust Robinson cuts target price to $13 from $14
* Callaway Golf Co : Compass Point cuts price target to $20 from $21
* Callaway Golf Co : Jefferies cuts target price to $17 from $20
* Canadian National Railway Co : Citigroup raises price target to $80 from $68
* Canadian National Railway Co : Credit Suisse raises target price to $86 from $84
* Canadian National Railway Co : Evercore ISI raises target price to $89 from $81
* Canadian National Railway Co : Stephens raises target price to $82 from $80
* Carvana Co : Needham raises price target to $100 from $75
* Cathay General Bancorp : D.A. Davidson raises target price to $28 from $23
* Cathay General Bancorp : Wedbush raises target price to $29 from $25
* CBRE Group Inc : Raymond James cuts target price to $57 from $63
* Centerstate Bank Corp : D.A. Davidson cuts target price by $3.50 to $18.50
* Chart Industries Inc : Citigroup cuts price target to $43 from $45
* Check Point Software Technologies : Cowen and Company raises PT to $105 from $100
* Check Point Software Technologies : Jefferies raises PT to $110 from $100
* Check Point Software Technologies Ltd : BMO cuts target price to $120 from $125
* Check Point Software Technologies Ltd : Citigroup raises PT to $108 from $105
* Check Point Software Technologies Ltd : RBC raises target price to $108 from $105
* CIT Group Inc : Oppenheimer raises target price to $58 from $54
* Citigroup Inc : Oppenheimer raises target price to $96 from $87
* Cms Energy Corp : Citigroup raises price target to $60 from $59
* CNX Resources Corp : MKM Partners cuts to neutral from buy
* CNX Resources Corp : MKM Partners raises fair value to $12 from $11
* CNX Resources Corp : Raymond James raises to outperform from underperform
* Cognex Corp : Raymond James raises target price to $60 from $48
* Columbia Sportswear Co : Guggenheim cuts target price to $90 from $110
* Corporate Office Properties Trust : Mizuho cuts price target to $26 from $32
* Crown Castle International Corp : Credit Suisse initiates with $149 target price
* Crown Castle International Corp : Credit Suisse initiates with neutral rating
* Delek US Holdings Inc : Raymond James raises target price to $23 from $20
* Dexcom Inc : Canaccord Genuity raises target price to $370 from $300
* Discovery Inc : RBC initiates with outperform, $26 target price
* Donnelley Financial Solutions Inc : D.A.
- 04/28/2020
|
Home Healthcare Market 2020 Surprising Growth due to Covid 19 include Major Players Koninklijke Philips N.V., Air Liquide, Amedisys, Apple Home Healthcare, Arcadia and others
- NEW YORK, April 28, 2020 -- The world isn't just battling a health pandemic, but additionally a financial one, as the Novel Coronavirus (COVID – 19) throws its long shadow over.
- 04/28/2020
|
United States Nursing Care Industry Outlook and Forecast 2020-2025
- The "Nursing Care Market in US - Industry Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The US Nursing Care Market is expected to grow at a CAGR of over 5% during the period 2019-2025. This study considers the present scenario of the US
- 04/28/2020
|
U.S. Nursing Care Market Report 2020-2025: COVID-19, Increasing Sedentary Lifestyles, Health Insurance Reforms, Changes in Social Patterns
- The "Nursing Care Market in US - Industry Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
- 04/27/2020
|
Amedisys (AMED) Receives a Rating Update from a Top Analyst
- Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Amedisys (AMED) today and set a price target of $215.00. The company's shares closed
- 04/27/2020
|
Amedisys (AMED) Receives a Rating Update from a Top Analyst
- Oppenheimer analyst
Michael Wiederhorn
maintained a
Buy
rating on Amedisys (
AMED
–
Research Report
) today and set a price target of
$215.00
. The company’s shares closed last Friday at $186.50.
According to
TipRanks.com
, Wiederhorn is a top 100 an
- 04/27/2020
|
Amedisys to acquire AseraCare Hospice for $235M in cash AMED
- Amedisys to acquire AseraCare Hospice for $235M in cash AMED
- 04/27/2020
|
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
- Pre-open movers
U.S. stock futures traded higher in early pre-market trade, ahead of earnings from Lincoln Electric Holdings, Inc. (NASDAQ: LECO), PPG Industries, Inc. (NYSE:...
- 04/27/2020
|
BRIEF-Amedisys Signs Definitive Agreement To Acquire Aseracare Hospice
|
Amedisys Signs Definitive Agreement to Acquire AseraCare Hospice for $203M Net of Tax Asset
|
Amedisys Signs Definitive Agreement to Acquire AseraCare Hospice
- Amedisys, Inc. (AMED), a leading provider of home health, hospice and personal care, announced today that it has, through one of its wholly owned subsidiaries, signed a definitive agreement to acquire Homecare Preferred Choice, Inc., doing business as AseraCare Hospice (“AseraCare Hospice”), a national hospice care provider with an executive office in Plano, Texas and administrative support center in Fort Smith, Arkansas. Founded in 1994, AseraCare Hospice cares for more than 2,100 patients daily and employs more than 1,200 hospice professionals in 44 locations across 14 states, generating approximately $117 million in annual revenues. Under the terms of the agreement, expected to close on, or around, June 1, 2020, pending regulatory approvals, Amedisys will acquire 100 percent of the ownership interests in AseraCare Hospice for a cash purchase price of $235 million, which is inclusive of a $32 million tax asset bringing the net purchase price to $203 million.
- 04/27/2020
|
Amedisys Signs Definitive Agreement to Acquire AseraCare Hospice
- BATON ROUGE, La., April 27, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and personal care,...
- 04/27/2020
|
Macquarie Group Ltd. Increases Stake in Amedisys Inc (NASDAQ:AMED)
- Macquarie Group Ltd. increased its position in shares of Amedisys Inc (NASDAQ:AMED) by 64.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 24,386 shares of the health services provider’s stock after purchasing an additional 9,582 shares during the period. Macquarie Group Ltd.’s holdings in Amedisys were worth $4,070,000 as of its most recent […]
- 04/27/2020
|
Amedisys Signs Definitive Agreement to Acquire AseraCare Hospice
|
British Airways Pensions Investment Management Ltd Has $11.36 Million Holdings in Amedisys Inc (NASDAQ:AMED)
- British Airways Pensions Investment Management Ltd lifted its stake in Amedisys Inc (NASDAQ:AMED) by 19.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 61,868 shares of the health services provider’s stock after buying an additional 9,985 shares during the period. […]
- 04/26/2020
|
Two coronavirus victims among latest deaths and funeral notices
- There have been 133 notices and acknowledgements printed in our sister title, The Herald, over the past two weeks
- 04/26/2020
|
How Should Investors Feel About Amedisys, Inc.’s (NASDAQ:AMED) CEO Pay?
- In 2014, Paul Kusserow was appointed CEO of Amedisys, Inc. (NASDAQ:AMED). This report will, first, examine the CEO...
- 04/25/2020
|
2,683 Shares in Amedisys Inc (NASDAQ:AMED) Bought by Assenagon Asset Management S.A.
- Assenagon Asset Management S.A. purchased a new stake in Amedisys Inc (NASDAQ:AMED) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 2,683 shares of the health services provider’s stock, valued at approximately $492,000. Other hedge funds have also recently made changes to […]
- 04/25/2020
|
The US nursing care market is expected to grow at a CAGR of over 5% during the period 2019-2025
- With the Purchase of US Nursing Care Market Report,Receive a FREE Copy of Market Impact of COVID-19 on Businesses.Read the full report: https://www.reportlinker.com/p05888074/?utm_source=PRN The US nursing care market is expected to grow at a CAGR of over 5% during the period 2019–2025.The US nursing
- 04/24/2020
|
United States' Nursing Care Market, 2020-2025 - Outbreak of COVID-19 Solidifies the Need to Address the Surge in Demand for Nurses - ResearchAndMarkets.com
- The "Nursing Care Market in US - Industry Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
- 04/24/2020
|
BofA parses winners, losers in healthcare provider stimulus
- News is free at Seeking Alpha.This post is a Notable Call. Notable Calls are a Premium feature.To access this and other Notable Calls, try a free trial to Seeking Alpha Premium.
- 04/23/2020
|
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
- Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 04/23/2020
|
3 Reasons Why Growth Investors Shouldn't Overlook Amedisys (AMED)
- Amedisys (AMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 04/23/2020
|
Quest Diagnostics (DGX) in Focus: Stock Moves 5.4% Higher
- Quest Diagnostics (DGX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- 04/23/2020
|
Anderson Fisher LLC Invests $67,000 in Amedisys Inc (NASDAQ:AMED)
- Anderson Fisher LLC acquired a new position in shares of Amedisys Inc (NASDAQ:AMED) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 363 shares of the health services provider’s stock, valued at approximately $67,000. Several other hedge funds have also recently bought and […]
- 04/23/2020
|
Amedisys Earns Top Ratings Amid Expansion Drive; Earnings On Tap
- Amedisys has a 98 Composite Rating, of a best-possible 99, and holds the No. 1 rank among its peers in the Medical-Outpatient/Home Care industry group.
- 04/22/2020
|
Add These 4 Stocks With Remarkable Interest Coverage Ratio
- Debt, which is crucial for most of the companies to finance operations, comes at a cost called interest. Interest expense has a direct bearing on the profits of a company.
- 04/22/2020
|
Amedisys (AMED) Receives a Buy from RBC Capital
- RBC Capital analyst Frank Morgan maintained a Buy rating on Amedisys (AMED) today and set a price target of $218.00. The company's shares closed last
- 04/20/2020
|
First Citizens Bank & Trust Co. Has $256,000 Holdings in Amedisys Inc (NASDAQ:AMED)
- First Citizens Bank & Trust Co. boosted its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 7.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,395 shares of the health services provider’s stock after buying an additional 101 shares […]
- 04/20/2020
|
Best Long-Term Stocks To Buy And Watch Now
- The best long-term stocks feature stable earnings growth and steady price gains. Here's how to find, buy and sell them — and a list to get you started.
- 04/17/2020
|
Amedisys receives cash payment of $96M in CARES Act assitance AMED
- Amedisys receives cash payment of $96M in CARES Act assitance AMED
- 04/17/2020
|
10 Stocks Hitting All-Time Highs Amid The COVID-19 Pandemic
- The COVID-19 pandemic staggered economic activity and decreased consumer spending. Some companies have benefited from the extra resources needed to help curb the pandemic and keep...
- 04/16/2020
|
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
- Is (AMED) Outperforming Other Medical Stocks This Year?
- 04/16/2020
|
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
- Is (AMED) Outperforming Other Medical Stocks This Year?
- 04/16/2020
|
Bet on These 5 Low Leverage Stocks as Q1 Earnings Starts
- To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable. A debt-free corporation is hard to find.
- 04/16/2020
|
Stocks That Hit 52-Week Highs On Thursday
- On Thursday morning, 49 companies hit new 52-week highs.
Noteworthy Mentions:
Amazon.com (NASDAQ: AMZN) was the largest firm on a market cap basis to set a new 52-week...
- 04/16/2020
|
Amedisys (NASDAQ:AMED) Hits New 1-Year High at $205.88
- Shares of Amedisys Inc (NASDAQ:AMED) reached a new 52-week high on Tuesday . The company traded as high as $205.88 and last traded at $205.88, with a volume of 921 shares trading hands. The stock had previously closed at $196.36. A number of equities research analysts recently weighed in on AMED shares. SunTrust Banks raised […]
- 04/16/2020
|
These Six Long-Term Leaders Are Now Actionable
- After the April 2 follow-through day on the S&P; 500 and the April 6 Tom Petty "Won't Back Down" FTD on the Nasdaq, we are making some updates to IBD's Long-Term Leaders Portfolio and Watchlist. These Current Long-Term Leaders Are Actionable Five Long-Term Leaders Portfolio stocks are ready to buy: Amedisys (AMED), Dollar General (DG), Masimo (MASI), Microsoft (MSFT) and Thermo Fisher Scientific (TMO)....
- 04/15/2020
|
Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know
- Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/15/2020
|
Amedisys (AMED) Upgraded to Buy: Here's Why
- Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/15/2020
|
Amedisys (AMED) Is Up 8.62% in One Week: What You Should Know
- Does Amedisys (AMED) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/15/2020
|
Amedisys Breaks Out To New Highs
- Amedisys, a nursing home care provider, broke out over a 202.86 entry after clearing an early entry at 190.50 last week. This was an outside day for a long-term leader.
- 04/15/2020
|
Amedisys (AMED) Hits 52-Week High, Can the Run Continue?
- Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 04/15/2020
|
Amedisys (AMED) Hits 52-Week High, Can the Run Continue?
- Amedisys (AMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- 04/15/2020
|
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
- Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
- 04/15/2020
|
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
- Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
- 04/15/2020
|
How Does Amedisys's (NASDAQ:AMED) P/E Compare To Its Industry, After Its Big Share Price Gain?
- Amedisys (NASDAQ:AMED) shares have had a really impressive month, gaining 45%, after some slippage. Looking back a bit...
- 04/15/2020
|
What Is Amedisys’s (NASDAQ:AMED) P/E Ratio After Its Share Price Rocketed?
- Amedisys (NASDAQ:AMED) shareholders are no doubt pleased to see that the share price has had a great month, posting a...
- 04/15/2020
|
Franklin Resources Inc. Purchases New Holdings in Amedisys Inc (NASDAQ:AMED)
- Franklin Resources Inc. purchased a new stake in Amedisys Inc (NASDAQ:AMED) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,408 shares of the health services provider’s stock, valued at approximately $235,000. Other institutional investors and hedge funds […]
- 04/15/2020
|
Stocks That Hit 52-Week Highs On Tuesday
|
Amedisys Announces First Quarter Earnings Release and Conference Call Date
- Amedisys, Inc. (AMED), announced today that it will report results for the first quarter ended March 31, 2020, after the market closes on May 6, 2020. The Company will host an investor conference call to discuss these results at 11:00 a.m. ET on May 7, 2020. To participate on the conference call, please call a few minutes before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll).
- 04/14/2020
|
Amedisys Announces First Quarter Earnings Release and Conference Call Date
- BATON ROUGE, La., April 14, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), announced today that it will report results for the first quarter...
- 04/14/2020
|
